Transbuccal insulin - MidaSol

Drug Profile

Transbuccal insulin - MidaSol

Alternative Names: Insulin - MidaSol; Insulin buccal soluble film - Midatech Pharma; Insulin nanoparticles buccal film - Midasol; MidaForm insulin PharmFilm; MidaForm™-Insulin-Pharmfilm®; MSL-001; MSRX-301; MTD-101; Nanoparticle insulin

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MidaSol Therapeutics; Midatech; MonoSol Rx
  • Developer MidaSol Therapeutics
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 27 Jul 2015 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (Buccal) (ACTRN12615000495527)
  • 01 Jul 2015 Midatech and Monosol plan a phase II trial Type-I diabetes mellitus in Australia (ACTRN12615000495527)
  • 24 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top